Welcome to our dedicated page for BLU news (Ticker: BLU), a resource for investors and traders seeking the latest updates and insights on BLU stock.
BELLUS Health Inc. (BLU) is an innovative biopharmaceutical development company dedicated to creating novel therapeutics for conditions with high unmet medical needs. Based in Canada, the company’s flagship project is BLU-5937, a groundbreaking drug candidate designed to treat chronic cough. Chronic cough, persisting for over eight weeks, significantly impacts the quality of life of more than 2.7 million patients in the United States alone. By targeting the P2X3 receptor, BLU-5937 offers a promising solution for patients who do not respond to existing treatments.
The drug candidate is a potent, highly selective, orally bioavailable small molecule antagonist of the P2X3 receptor, making it a potential best-in-class treatment option. The rights to BLU-5937 were acquired through a license agreement with the Neomed Institute in February 2017.
Beyond its lead project, BELLUS Health has vested interests in various partnered drug development initiatives, showcasing its broad commitment to addressing diverse medical challenges. The company's strategic partnerships and cutting-edge research underscore its pivotal role in the biopharmaceutical industry.
With continuous advancements and strong economic interests in multiple projects, BELLUS Health is positioned as a key player in developing revolutionary therapies that could significantly improve patients' lives. Investors and stakeholders remain keenly interested in the company's progress and future potential.
BELLUS Health reported a positive interim analysis of its Phase 2b SOOTHE trial for BLU-5937, showing at least one effective dose for treating refractory chronic cough (RCC). Both the SOOTHE and Phase 2a BLUEPRINT trials are fully enrolled, with topline results anticipated in December 2021. The company ended Q3 2021 with
BELLUS Health, a clinical-stage biopharmaceutical company, announced participation by CEO Roberto Bellini in two upcoming healthcare investor conferences. The conferences are the Jefferies London Healthcare Conference on November 18, 2021, and the Evercore ISI HealthCONx Virtual Conference on December 1, 2021. Webcasts will be available on the company's website. BELLUS Health focuses on developing treatments for refractory chronic cough (RCC) and related disorders. Currently, there are no effective therapies approved for RCC, which affects about 9 million patients in the U.S.
BELLUS Health (Nasdaq: BLU) announced a virtual analyst event on
BELLUS Health has completed patient enrollment in two pivotal clinical trials: the Phase 2b SOOTHE trial for BLU-5937 in refractory chronic cough (RCC) and the Phase 2a BLUEPRINT trial for chronic pruritus associated with atopic dermatitis. Topline results are anticipated in
BELLUS Health announced positive interim results from its Phase 2b SOOTHE trial for BLU-5937, a treatment for refractory chronic cough. The analysis confirmed a high probability of clinical efficacy for at least one dosage, with significant reductions in cough frequency and minimal adverse events reported. The favorable data will accelerate planning for the Phase 3 program, with topline results expected in Q4 2021. This trial, involving over 300 participants, aims to evaluate the efficacy of multiple dosages of BLU-5937 against a placebo.
BELLUS Health, a clinical-stage biopharmaceutical company, announced that CEO Roberto Bellini will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 a.m. ET. BELLUS Health is focused on developing therapies for refractory chronic cough (RCC) and related disorders. Currently, approximately 9 million patients in the U.S. suffer from RCC, which has no specific approved treatment. Their product candidate, BLU-5937, also targets chronic pruritus associated with atopic dermatitis, impacting up to 10% of U.S. adults.
BELLUS Health, a clinical-stage biopharmaceutical company, announced that an abstract detailing additional data from its RELIEF Phase 2a trial will be presented orally at the European Respiratory Society International Congress 2021 from September 5-8. The trial focuses on BLU-5937, a selective P2X3 antagonist, for treating refractory chronic cough (RCC). Notable improvements in cough severity and quality of life were observed during the trial. BELLUS aims to further demonstrate its efficacy in ongoing trials. RCC significantly impacts patients' lives, with millions affected in the United States.
BELLUS Health (Nasdaq:BLU) reported Q2 2021 financial results highlighting a net loss of US$17.8 million (US$0.23 per share), compared to US$8.4 million (US$0.14 per share) in Q2 2020. The company is advancing its Phase 2 trials for BLU-5937, targeting refractory chronic cough and chronic pruritus, with topline results expected in Q4 2021. Cash reserves stood at US$72.3 million, down from US$98.3 million at the end of 2020, but sufficient to support operations until end of 2022. Key presentations are scheduled at international conferences.
BELLUS Health, a clinical-stage biopharmaceutical company, announced that President and CEO Roberto Bellini will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 10:30 a.m. ET. This event will focus on the development of novel therapeutics for refractory chronic cough (RCC) and other disorders related to hypersensitization. The live webcast can be accessed on the company's website, with an archived version available post-event.
BELLUS Health, a clinical-stage biopharmaceutical company (Nasdaq: BLU), announced that CEO Roberto Bellini will participate in the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 9:10 a.m. ET. The event will focus on BELLUS's development of novel therapeutics for refractory chronic cough (RCC) and other hypersensitization-related disorders. RCC affects about 9 million patients in the U.S., with no approved specific therapies currently available. For further details, a live webcast will be accessible through the company's website.
FAQ
What is the market cap of BLU (BLU)?
What is BELLUS Health Inc.?
What is BLU-5937?
How does BLU-5937 work?
What is chronic cough?
When did BELLUS Health acquire the rights to BLU-5937?
Who are the potential beneficiaries of BLU-5937?
What other projects is BELLUS Health involved in?
Where is BELLUS Health headquartered?
Why is BLU-5937 considered a potential best-in-class drug?
How does BELLUS Health contribute to the biopharmaceutical industry?
